Company Description: Endure Biotherapeutics (“Endure Bio”®) is developing engineered engraftable live biotherapeutics for metabolic diseases by genetically engineering human native bacteria to express therapeutic compounds. Endure’s advantage is its Engineered Native Bacteria (ENB) platform technology. Unlike other microbiome therapeutics, ENB-based biotherapeutics overcome the traditional challenges of first-generation products, allowing for engraftable knock-in function with infrequent administration, delivering potentially curative solutions that remain resident and endure the host environment. The company has an initial focus on orphan disease applications, specifically targeting phenylketonuria (PKU), a >$2.4 billion market with significant unmet need. Our broadly applicable platform has the potential to span therapeutic areas including metabolism, oncology, and IBD, leading to significant opportunities for partnerships with other companies to develop and commercialize.